Differential and limited expression of mutant alleles in multiple myeloma

Blood

Volumn 124, Issue 20, 2014, Pages 3110-3117

  Rashid, Naim U ^a,b   Sperling, Adam S ^a   Bolli, Niccolo ^c,d   Wedge, David C ^c   Van Loo, Peter ^c,e   Tai, Yu Tzu ^a   Shammas, Masood A ^a,f   Fulciniti, Mariateresa ^a   Samur, Mehmet K ^a,b   Richardson, Paul G ^a   Magrangeas, Florence ^g   Minvielle, Stephane ^g   Futreal, P Andrew ^h   Anderson, Kenneth C ^a   Avet Loiseau, Herve ^i,j   Campbell, Peter J ^c,d   Parmigiani, Giovanni ^b   Munshi, Nikhil C ^a,f  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f VA BOSTON HEALTHCARE SYSTEM   (United States)

^g UNIVERSITÉ DE NANTES   (France)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

ⁱ CHU RANGUEIL   (France)

^j CANCER RESEARCH CENTER OF TOULOUSE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALLELE; ARTICLE; CANCER CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; HUMAN; MULTIPLE MYELOMA; RNA SEQUENCE; GENE EXPRESSION REGULATION; GENETICS; MUTATION; SEQUENCE ANALYSIS;

DNA; RNA;

ALLELES; DNA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MULTIPLE MYELOMA; MUTATION; RNA; SEQUENCE ANALYSIS, RNA;

EID: 84911897497     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-04-569327     Document Type: Article

References (24)

1. Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 2011;364(11):1046-1060.
2. Fonseca R, Bergsagel PL, Drach J, et al; International Myeloma Working Group. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009;23(12): 2210-2221.
3. Girnius S, Munshi NC. Individualized therapy in multiple myeloma: are we there? Semin Oncol. 2013;40(5):567-576.
4. Alexandrov LB, Nik-Zainal S, Wedge DC, et al; Australian Pancreatic Cancer Genome Initiative; ICGC Breast Cancer Consortium; ICGC MMML-Seq Consortium; ICGC PedBrain. Signatures of mutational processes in human cancer [published correction appears in Nature. 2013; 502(7470):258]. Nature. 2013;500(7463): 415-421.
5. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339): 467-472.
6. Egan JB, Shi CX, Tembe W, et al. Whole-genome sequencing of multiple myeloma from diagnosis to plasma cell leukemia reveals genomic initiating events, evolution, and clonal tides. Blood. 2012; 120(5):1060-1066.
7. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t (4;14) and t(11;14) myeloma. Blood. 2012; 120(5):1077-1086.
8. Walker BA, Wardell CP, Melchor L, et al. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms. Leukemia. 2014;28(2): 384-390.
9. Bolli N, Avet-Loiseau H, Wedge DC, et al. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014;5:2997-3010.
10. Watson IR, Takahashi K, Futreal PA, Chin L. Emerging patterns of somatic mutations in cancer. Nat Rev Genet. 2013;14(10): 703-718.
11. Trapnell C, Pachter L, Salzberg SL. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics. 2009;25(9):1105-1111.
12. Anders S. HTSeq: analysing high-throughput sequencing data with Python. http://www-huber. embl.de/users/anders/HTSeq/doc/overview.html. 2010. Accessed June 5th, 2014.
13. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12(1):323-337.
14. Li H, Handsaker B, Wysoker A, et al; 1000 Genome Project Data Processing Subgroup. The sequence alignment/map format and SAMtools. Bioinformatics. 2009;25(16): 2078-2079.
15. Quinn EM, Cormican P, Kenny EM, et al. Development of strategies for SNP detection in RNA-seq data: application to lymphoblastoid cell lines and evaluation using 1000 Genomes data. PLoS ONE. 2013;8(3): e58815.
16. Shen S, Park JW, Huang J, et al. MATS: a Bayesian framework for flexible detection of differential alternative splicing from RNA-Seq data. Nucleic Acids Res. 2012; 40(8):e61.
17. Govindan R, Ding L, Griffith M, et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell. 2012;150(6): 1121-1134.
18. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature. 2012;486(7403): 395-399.
19. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-1812.
20. Wood LD, Parsons DW, Jones S, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007;318(5853): 1108-1113.
21. Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-218.
22. Callahan MK, Rampal R, Harding JJ, et al. Progression of RAS-mutant leukemia during RAF inhibitor treatment. N Engl J Med. 2012;367(24): 2316-2321.
23. Robert C, Arnault JP, Mateus C. RAF inhibition and induction of cutaneous squamous cell carcinoma. Curr Opin Oncol. 2011;23(2): 177-182.
24. Mahindra A, Laubach J, Raje N, Munshi N, Richardson PG, Anderson K. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012;9(3): 135-143.